Paraxanthine (Enfinity)
Paraxanthine is the caffeine metabolite to watch for cleaner focus, with Yoo 2024 testing cognition after a 10-km run. The upside is plausible for energy and attention, but the human evidence remains small and brand-linked.
Paraxanthine (Enfinity) scored 5.6 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Stimulant / Methylxanthine.
What It Is
Paraxanthine (Enfinity) scores 5.6/10 because its strongest case is acute cognition, energy, and exercise-adjacent performance, with weaker support outside that lane. The best read is practical and narrow: match the intervention to caffeine-sensitive readers who want a metabolite-focused stimulant profile.
The main evidence anchor is Yoo et al. 2021. Yoo et al. 2024 adds important context, while Walton et al. 2023 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the supplement evidence is new, small, and still needs independent replication across ordinary users. This report treats Paraxanthine as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 100-300 mg/day in commercial and trial-style use | 100-300 mg/day in commercial and trial-style use |
Protocols
Conservative research comparison Mixed
- Dose
- 100-300 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 1.53
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.9 | 0.725 | |
| Breadth of Benefits | 15% | 2.5 | 0.375 | |
| Evidence Quality | 25% | 1.8 | 0.450 | |
| Speed of Onset | 10% | 3.8 | 0.380 | |
| Durability | 10% | 2.1 | 0.210 | |
| Bioindividuality Upside | 15% | 2.6 | 0.390 | |
| Total | 2.530 |
Upside Rationale
Paraxanthine (Enfinity) scores 5.6/10 because its upside is concentrated in acute cognition, energy, and exercise-adjacent performance. The clearest anchor is double-blind crossover cognition work and emerging exercise data, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (3.8/5.0): Paraxanthine earns this efficacy score because the best signals map to acute cognition, energy, and exercise-adjacent performance. Yoo et al. 2021 is the main anchor, while Yoo et al. 2024 helps define where the signal remains preliminary.
Breadth of Benefits (3.0/5.0): Paraxanthine has limited breadth outside its core lane. The report gives more credit where the evidence matches caffeine-sensitive readers who want a metabolite-focused stimulant profile, and less where endpoints drift into unrelated systems.
Evidence Quality (3.0/5.0): Paraxanthine evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Yoo et al. 2021 and Walton et al. 2023 keep the score useful without overstating certainty.
Speed of Onset (4.2/5.0): Paraxanthine can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (2.6/5.0): Paraxanthine durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (3.2/5.0): Paraxanthine has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Yoo et al. 2024 is useful for defining that context.
Downside contribution: 0.89 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.7 | 0.510 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 2.2 | 0.110 | |
| Time/Effort Burden | 5% | 1.4 | 0.070 | |
| Opportunity Cost | 5% | 1.8 | 0.090 | |
| Dependency / Withdrawal | 15% | 1.8 | 0.270 | |
| Reversibility | 25% | 1.4 | 0.350 | |
| Total | 1.670 | |||
| Harm subtotal × 1.4 | 1.960 | |||
| Opportunity subtotal × 1.0 | 0.270 | |||
| Combined downside | 2.230 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.890 |
Downside Rationale
Paraxanthine (Enfinity) downside is driven by the supplement evidence is new, small, and still needs independent replication across ordinary users. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (2.0/5.0): Paraxanthine safety concerns are manageable for some users and unacceptable for others depending on dose, diagnosis, medication use, and source quality. Yoo et al. 2024 is the main safety anchor for this dimension.
Side Effects (2.2/5.0): Paraxanthine side effects matter because the likely use cases often depend on subjective feel, stimulation, digestion, sleep, or skin response. Yoo et al. 2021 helps frame expected benefits against tolerability.
Interaction Risk (2.3/5.0): Paraxanthine interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (2.4/5.0): Paraxanthine supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. Walton et al. 2023 is especially relevant when product trust is part of the risk.
Cost (2.3/5.0): Paraxanthine cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (2.2/5.0): Paraxanthine regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (2.6/5.0): Paraxanthine bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Verdict
Paraxanthine is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when Paraxanthine is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
✅ Best for: Caffeine-sensitive users testing focus and energy alternatives while recognizing the industry-funded evidence base. Paraxanthine makes the most sense when the reader can define the target outcome in advance, compare Paraxanthine with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid Paraxanthine when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using Paraxanthine as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 6.0/10
Score: 6.0/10Paraxanthine scores 6.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Yoo C. et al. 2021, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Paraxanthine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Energy / Fatigue: 6.2/10
Score: 6.2/10Paraxanthine scores 6.2/10 for energy because the most plausible benefit is acute perceived energy or stimulant-like activation. The strongest support comes from Yoo C. et al. 2021, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Paraxanthine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Reaction Time / Coordination: 5.5/10
Score: 5.5/10Paraxanthine scores 5.5/10 for reaction time because the reported benefit is most likely to show up on short-latency cognitive or performance tasks. The strongest support comes from Yoo C. et al. 2021, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Paraxanthine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Endurance / Cardio: 5.0/10
Score: 5.0/10Paraxanthine scores 5.0/10 for endurance cardio because exercise studies are suggestive but too small to rate as a core endurance tool. The strongest support comes from Yoo C. et al. 2021, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Paraxanthine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Paraxanthine actually do?
Paraxanthine mainly acts through the biology described in this report, and the best concise source is Yoo C. et al. 2021. Paraxanthine should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much Paraxanthine is typically used?
Paraxanthine is usually discussed around 100-300 mg/day in commercial and trial-style use, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. Paraxanthine should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for Paraxanthine?
Paraxanthine has an evidence profile led by Yoo C. et al. 2021 and the other sources in the evidence table. Paraxanthine receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is Paraxanthine safe long term?
Paraxanthine looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. Paraxanthine earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid Paraxanthine?
Paraxanthine should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. Paraxanthine also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does Paraxanthine work?
Paraxanthine may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. Paraxanthine should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is Paraxanthine different from nearby alternatives?
Paraxanthine differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare Paraxanthine with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the Paraxanthine score change?
Paraxanthine would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. Paraxanthine would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Paraxanthine could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Paraxanthine could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.8 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.6 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 4.4 / 10 ⚠️ Caution |
BioHarmony Engine v1.0
Key Evidence Sources
- Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memory and Helps Sustain Attention in a Double-Blind, Placebo-Controlled, Crossover Trial. Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memory and Helps Sustain Attention in a Double-Blind, Placebo-Controlled, Cro
- Paraxanthine provides greater improvement in cognitive function than caffeine after performing a 10-km run. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- Paraxanthine Supplementation Increases Muscle Mass, Strength, and Endurance in Mice. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- A Dose-Response Study to Examine Paraxanthine's Impact on Energy Expenditure, Hunger, Appetite, and Lipolysis. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Paraxanthine safety and comparison to caffeine. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- An assessment of mutagenicity, genotoxicity, acute-, subacute and subchronic oral toxicity of paraxanthine (1,7-dimethylxanthine). Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- The effect of caffeine dose on caffeine and paraxanthine changes in serum and saliva and CYP1A2 enzyme activity in athletes: a randomized placebo-controlled crossover trial. The effect of caffeine dose on caffeine and paraxanthine changes in serum and saliva and CYP1A2 enzyme activity in athletes: a randomized pl
- Wikidata entity Q414971. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Dietary Supplements. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Yoo 2021: Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memory and Helps Sustain Attention in a Double-Blind, Placebo-Controlled, Crossover Trial.
Pre-RCT-Era Pharmacology and Use
Citations: Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memo..., Paraxanthine provides greater improvement in cognitive function tha..., Paraxanthine safety and comparison to caffeine
Traditional Medicine Systems
Citations: Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memo..., Paraxanthine provides greater improvement in cognitive function tha..., Paraxanthine safety and comparison to caffeine
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Resting Heart Rate During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Primary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Clean Focus Scale 1-5 | During | Expected Up
- Chest Tightness Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Palpitations, chest pain, or panic
- Stacking with high caffeine late in the day
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.530 − 0.890 = 0.640
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.640 / 5) × 5 = 5.6 / 10
Further learning
Paraxanthine: The Energy Supplement Putting Caffeine Out of Business
Paraxanthine is a natural metabolite of caffeine that, when consumed with caffeine together from green tea, results in energy-boosting effects 4 times greater than…
Paraxanthine: Ultimate Caffeine Upgrade
Is there a better alternative to coffee? A drink that gives you all the best benefits of caffeine but without the drawbacks? Our guests…
